Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Enzyme Therapy Prior Auth | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedUnitedHealthcarePolicy CS2026D0052AH

    Medical Therapies for Enzyme Deficiencies

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy CS2026D0052AH alerts

    Get alerted when Policy CS2026D0052AH changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    UnitedHealthcare Community Plan coverage and prior authorization for specified enzyme replacement, enzyme-substitution, and related therapies for inherited enzyme deficiencies, with state-specific Medicaid exceptions.

    Policy Summary
    PayerUnitedHealthcare
    PolicyMedical Therapies for Enzyme Deficiencies
    Policy CodePolicy CS2026D0052AH
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateNot specified
    Key ActionSubmit diagnostic confirmation, clinical findings, treatment history, FDA-labeled dosing, and clinical response documentation for the requested drug and therapy phase.
    SourceLink
    POLICY UPDATE CHANGES

    Avlayah and Loargys were added to the applicable medical therapies for enzyme deficiencies for all states.

    Lumizyme, Nexviazyme, and Pombiliti were added as applicable products for Indiana only.

    New initial and continuation authorization criteria were added for Avlayah for neurologic manifestations of MPS II.

    New initial and continuation authorization criteria were added for Loargys for hyperargininemia due to arginase 1 deficiency.

    Elaprase criteria were revised to prohibit concurrent use with Avlayah.

    Fabrazyme criteria were revised to prohibit concurrent use with another disease-modifying Fabry disease therapy.

    Applicable codes were added for Avlayah.

    Applicable codes were added for Loargys.

    2New all-state products
    18Products listed
    12 monthsMaximum authorization
    2MPS II combinations prohibited
    8State jurisdictions with instructions

    Drug-Specific Coverage Criteria

    Aldurazyme (laronidase) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of an MPS I syndrome confirmed by ONE of the following

      • Hurler variant (severe MPS I; MPS IH)
      • Hurler-Scheie variant (attenuated MPS I; MPS IHS)
      • Scheie variant (attenuated MPS I; MPS IS)
    • Diagnosis of MPS I confirmed by ONE of the following

      • Deficiency or absence of fibroblast or leukocyte alpha-L-iduronidase enzyme activity
    Policy Summary
    PayerUnitedHealthcare
    PolicyMedical Therapies for Enzyme Deficiencies
    Policy CodePolicy CS2026D0052AH
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateNot specified
    Key ActionSubmit diagnostic confirmation, clinical findings, treatment history, FDA-labeled dosing, and clinical response documentation for the requested drug and therapy phase.
    SourceLink
    On This Page
    Drug-Specific Coverage CriteriaApplicable Codes and Coding RequirementsAuthorization, Documentation, and Denial RisksPolicy BackgroundDisease and Clinical DefinitionsInitial Therapy Decision CriteriaContinuation and Reauthorization CriteriaRequired Treatment TransitionAuthorization Period Limits
  1. Molecular genetic confirmation of mutations in the alpha-L-iduronidase gene
  2. Presence of clinical signs and symptoms of the disease (e.g., asymptomatic with affected older sibling, cardiac abnormalities, corneal clouding, dysostosis multiplex, hepatomegaly, restrictive lung disease)
  3. Dosing is in accordance with FDA-approved labeling
  4. Initial authorization will be for no more than 12 months
  5. Aldurazyme (laronidase) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with laronidase therapy
    • Patient has experienced a positive clinical response to laronidase therapy (e.g., improved endurance, improved functional capacity, reduced urine dermatan sulfate/heparan sulfate excretion)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Avlayah (tividenofusp alfa) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of MPS II confirmed by ONE of the following

      • Deficiency in iduronate 2-sulfatase enzyme activity in fibroblasts or leukocytes combined with normal activity of another sulfatase
      • Molecular genetic testing for deletion or mutations in the iduronate 2-sulfatase gene
    • Presence of clinical signs and symptoms of the disease (e.g., hepatosplenomegaly, skeletal deformities, dysostosis, neurocognitive decline, cardiovascular disorders)
    • Avlayah is not being used to treat MPS II in combination with Elaprase
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Avlayah (tividenofusp alfa) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with tividenofusp alfa
    • Patient has experienced a positive clinical response to tividenofusp alfa therapy (e.g., improved hearing, improved functional capacity, improved neurological symptoms, reduced spleen volume, reduced urine glycosaminoglycan excretion)
    • Avlayah is not being used to treat MPS II in combination with Elaprase
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Elaprase (idursulfase) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of MPS II confirmed by ONE of the following

      • Deficiency in iduronate 2-sulfatase enzyme activity in fibroblasts or leukocytes combined with normal activity of another sulfatase
      • Molecular genetic testing for deletion or mutations in the iduronate 2-sulfatase gene
    • Presence of clinical signs and symptoms of the disease (e.g., hepatosplenomegaly, skeletal deformities, dysostosis, neurocognitive decline, cardiovascular disorders)
    • Elaprase is not being used to treat MPS II in combination with Avlayah
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Elaprase (idursulfase) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with idursulfase therapy
    • Patient has experienced a positive clinical response to idursulfase therapy (e.g., improved endurance, improved functional capacity, reduced spleen volume, reduced urine GAG excretion)
    • Elaprase is not being used to treat MPS II in combination with Avlayah
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Elfabrio (pegunigalsidase alfa-iwxj) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of Fabry disease confirmed by ONE of the following

      • Absence or deficiency (< 5% of mean) of normal alpha-galactosidase A enzyme activity in leukocytes, dried blood spots, or serum
      • Molecular genetic testing for deletion or mutations in the galactosidase alpha gene
    • Presence of clinical signs and symptoms of Fabry disease (e.g., acroparesthesias, angiokeratomas, whorls, anhidrosis/hypohidrosis, renal disease, exercise or heat/cold intolerance)
    • Patient is not receiving Elfabrio in combination with another disease-modifying therapy for Fabry disease (e.g., Fabrazyme or Galafold)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Elfabrio (pegunigalsidase alfa-iwxj) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with pegunigalsidase alfa-iwxj therapy
    • Patient has experienced a positive clinical response to pegunigalsidase alfa-iwxj therapy (e.g., improved renal function, reduction in mean plasma GL-3 levels, decreased GL-3 inclusions)
    • Patient is not receiving Elfabrio in combination with another disease-modifying therapy for Fabry disease (e.g., Fabrazyme or Galafold)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Fabrazyme (agalsidase beta) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of Fabry disease confirmed by ONE of the following

      • Absence or deficiency (< 5% of mean) of normal alpha-galactosidase A enzyme activity in leukocytes, dried blood spots, or serum
      • Molecular genetic testing for deletion or mutations in the galactosidase alpha gene
    • Presence of clinical signs and symptoms of Fabry disease (e.g., acroparesthesias, angiokeratomas, whorls, anhidrosis/hypohidrosis, renal disease, exercise or heat/cold intolerance)
    • Patient is not receiving Fabrazyme in combination with another disease-modifying therapy for Fabry disease (e.g., Elfabrio or Galafold)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Fabrazyme (agalsidase beta) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with agalsidase beta therapy
    • Patient has experienced a positive clinical response to agalsidase beta therapy (e.g., improved renal function, reduction in mean plasma GL-3 levels, decreased GL-3 inclusions)
    • Patient is not receiving Fabrazyme in combination with another disease-modifying therapy for Fabry disease (e.g., Elfabrio or Galafold)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Kanuma (sebelipase alfa) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of lysosomal acid lipase deficiency confirmed by ONE of the following

      • Absence or deficiency of lysosomal acid lipase activity by dried blood spot test
      • Molecular genetic testing for deletion or mutations in the LIPA gene
    • Presence of clinical signs and symptoms (e.g., abdominal distention, hepatosplenomegaly, liver fibrosis, ascites)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Kanuma (sebelipase alfa) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with sebelipase alfa therapy
    • Patient has experienced a positive clinical response to sebelipase alfa therapy (e.g., improved disease symptoms or laboratory values such as LFTs, cholesterol, or triglycerides)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Lamzede (velmanase alfa-tycv) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of alpha-mannosidosis confirmed by ONE of the following

      • Absence or deficiency (< 10% of the laboratory-specific normal mean) of alpha-mannosidase enzyme activity
      • Molecular genetic testing for mutations in the MAN2B1 gene
    • Presence of clinical signs and symptoms (e.g., hepatosplenomegaly, skeletal abnormalities, ataxia, intellectual disability, hearing loss)
    • Lamzede is not being used to treat central nervous system manifestations of alpha-mannosidosis
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Lamzede (velmanase alfa-tycv) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with velmanase alfa-tycv therapy
    • Patient has experienced a positive clinical response to velmanase alfa-tycv therapy (e.g., improved motor function, improved pulmonary function)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Loargys (pegzilarginase) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of hyperargininemia (arginase 1 deficiency) confirmed by ONE of the following

      • Absence or deficiency of arginase 1 enzyme activity
      • Genetic variants in the ARG1 gene
    • Presence of clinical signs and symptoms (e.g., loss of motor skills, intellectual disability, developmental delay)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Loargys (pegzilarginase) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with pegzilarginase therapy
    • Patient has experienced a positive clinical response to pegzilarginase therapy (e.g., improved motor function, improved pulmonary function)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Lumizyme (alglucosidase alfa) — Initial Therapy Pathways

    Covered when ALL of the following are met:

    ALL of the following

    • One of the following Pompe disease pathways

      • Infantile-onset Pompe disease

        • ANY of the following

          • Acid alpha-glucosidase (GAA) activity is absent or deficient (< 1% of laboratory-specific normal mean) in skin fibroblasts
          • Molecular genetic testing confirms deletion or mutations in the GAA gene
        • Presence of clinical signs and symptoms (e.g., cardiac hypertrophy, respiratory distress, skeletal muscle weakness)
      • Late-onset Pompe disease

        • ANY of the following

          • GAA activity is absent or deficient (< 40% of laboratory-specific normal mean) in lymphocytes, fibroblasts, or muscle
          • Molecular genetic testing confirms deletion or mutations in the GAA gene
        • Presence of clinical signs and symptoms (e.g., cardiac hypertrophy, respiratory distress, skeletal muscle weakness)
    • Patient is not receiving Lumizyme in combination with another disease-modifying enzyme therapy for Pompe disease (e.g., Nexviazyme or Pombiliti)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Lumizyme (alglucosidase alfa) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with alglucosidase alfa therapy
    • Patient has experienced a positive clinical response to alglucosidase alfa therapy (e.g., improved respiratory or cardiac function, improved endurance)
    • Patient is not receiving Lumizyme in combination with another disease-modifying enzyme therapy for Pompe disease (e.g., Nexviazyme or Pombiliti)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Mepsevii (vestronidase alfa-vjbk) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of MPS VII confirmed by ONE of the following

      • Absence or deficiency of beta-glucuronidase activity in fibroblasts or leukocytes
      • Molecular genetic confirmation of mutations in the GUSB gene
    • Presence of clinical signs and symptoms (e.g., enlarged liver and spleen, joint limitations, airway obstruction or pulmonary problems, limitation of mobility while ambulatory)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Mepsevii (vestronidase alfa-vjbk) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with vestronidase alfa-vjbk therapy
    • Patient has experienced a positive clinical response to vestronidase alfa-vjbk therapy (e.g., improved endurance, improved functional capacity, improved pulmonary function)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Naglazyme (galsulfase) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of MPS VI confirmed by ONE of the following

      • Absence or deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase) activity in fibroblasts or leukocytes
      • Molecular genetic confirmation of mutations in the ASB gene (5q13-q14)
    • Presence of clinical signs and symptoms (e.g., kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, growth deficiency)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Naglazyme (galsulfase) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with galsulfase therapy
    • Patient has experienced a positive clinical response to galsulfase therapy (e.g., improved endurance, improved functional capacity, reduced urine dermatan sulfate excretion)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Nexviazyme (avalglucosidase alfa-ngpt) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • ANY of the following

      • GAA activity is absent or deficient (< 40% of laboratory-specific normal mean) in lymphocytes, fibroblasts, or muscle
      • Molecular genetic testing confirms deletion or mutations in the GAA gene
    • Presence of clinical signs and symptoms of late-onset Pompe disease (e.g., cardiac hypertrophy, respiratory distress, skeletal muscle weakness)
    • Patient is not receiving Nexviazyme in combination with another disease-modifying enzyme therapy for Pompe disease (e.g., Lumizyme or Pombiliti)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Nexviazyme (avalglucosidase alfa-ngpt) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with avalglucosidase alfa-ngpt therapy
    • Patient has experienced a positive clinical response to avalglucosidase alfa-ngpt therapy (e.g., improved respiratory or cardiac function, improved endurance)
    • Patient is not receiving Nexviazyme in combination with another disease-modifying enzyme therapy for Pompe disease (e.g., Lumizyme or Pombiliti)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Nulibry (fosdenopterin) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of MoCD type A confirmed by ONE of the following

      • Absence or deficiency of sulfite oxidase activity in fibroblasts
      • Molecular genetic testing confirms mutations in the MOCS1 gene
    • Clinical signs and symptoms within the first 28 days after birth (e.g., seizures, exaggerated startle response, high-pitched cry, hypotonia, hypertonia, feeding difficulties, elevated urinary sulfite or SSC, elevated xanthine, or low/absent uric acid)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Nulibry (fosdenopterin) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with fosdenopterin therapy
    • Patient has experienced a positive clinical response to fosdenopterin therapy (e.g., decreased seizures, improved feeding or responsiveness, improved motor function or growth, decreased sulfite/SSC or xanthine, increased uric acid)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Pombiliti (cipaglucosidase alfa-atga) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • ANY of the following

      • GAA activity is absent or deficient (< 40% of laboratory-specific normal mean) in lymphocytes, fibroblasts, or muscle
      • Molecular genetic testing confirms deletion or mutations in the GAA gene
    • Presence of clinical signs and symptoms of late-onset Pompe disease (e.g., cardiac hypertrophy, respiratory distress, skeletal muscle weakness)
    • Provider attests that the patient is not improving on current ERT (e.g., Lumizyme or Nexviazyme), which will be stopped
    • Patient weighs at least 40 kg
    • Prescribed in combination with oral Opfolda (miglustat)
    • Patient is not receiving Pombiliti in combination with another disease-modifying enzyme therapy for Pompe disease
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Pombiliti (cipaglucosidase alfa-atga) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with Pombiliti
    • Patient has experienced a positive clinical response to Pombiliti plus Opfolda therapy (e.g., improved respiratory or cardiac function, improved endurance)
    • Continues to be prescribed in combination with Opfolda (miglustat)
    • Patient is not receiving Pombiliti in combination with another disease-modifying enzyme therapy for Pompe disease
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Revcovi (elapegademase-lvlr) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of ADA-SCID
    • Deficiency of adenosine deaminase confirmed by ONE of the following

      • Deficiency or absence of ADA in plasma, lysed erythrocytes, fibroblasts, or chorionic villus
      • Increased dATP in erythrocyte lysates
      • Decreased ATP concentration in erythrocytes
      • Molecular genetic confirmation of mutations in both ADA1 alleles
      • Positive T-cell receptor excision circle screening
    • ONE of the following

      • Patient is not a suitable candidate for hematopoietic cell transplantation
      • Patient has failed hematopoietic cell transplantation
      • Patient is awaiting hematopoietic cell transplantation
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Revcovi (elapegademase-lvlr) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with elapegademase-lvlr therapy
    • Patient has experienced a positive clinical response (e.g., normalized plasma ADA activity or erythrocyte dATP levels, or improved disease symptoms)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Vimizim (elosulfase alfa) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of Morquio A syndrome confirmed by ONE of the following

      • Absence or deficiency of GALNS activity in fibroblasts or leukocytes
      • Molecular genetic testing confirms mutations in the GALNS gene (16q24.3)
    • Presence of clinical signs and symptoms (e.g., kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, growth deficiency)
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Vimizim (elosulfase alfa) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with elosulfase alfa therapy
    • Patient has experienced a positive clinical response (e.g., improved endurance, improved functional capacity, reduced urine keratan sulfate excretion)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Xenpozyme (olipudase alfa-rpcp) — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Diagnosis of ASMD type A/B or B confirmed by ONE of the following

      • Absence or deficiency of acid sphingomyelinase activity
      • Molecular genetic testing confirms mutations in the SMPD1 gene
    • Presence of clinical signs and symptoms (e.g., hepatosplenomegaly, elevated transaminases, mixed dyslipidemia, abnormal pulmonary function)
    • Xenpozyme is not being used to treat central nervous system manifestations of ASMD
    • Dosing is in accordance with FDA-approved labeling
    • Initial authorization will be for no more than 12 months

    Xenpozyme (olipudase alfa-rpcp) — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously received treatment with olipudase alfa-rpcp therapy
    • Patient has experienced a positive clinical response (e.g., reduced spleen or liver volume, improved transaminases, lipid profile, or pulmonary function)
    • Dosing is in accordance with FDA-approved labeling
    • Reauthorization will be for no more than 12 months

    Vimizim — Continuation Therapy Criteria

    Vimizim is not medically necessary for treatment of central nervous system manifestations of Morquio A syndrome.

    Xenpozyme — Initial Therapy Criteria

    Xenpozyme is not medically necessary for treatment of central nervous system manifestations of ASMD.

    Xenpozyme — Continuation Therapy Criteria

    Xenpozyme is not medically necessary for treatment of central nervous system manifestations of ASMD.

    Concurrent-Use Exclusion: Avlayah and Elaprase

    ALL of the following

    • Avlayah is not being used to treat MPS II in combination with Elaprase.

    Concurrent-Use Exclusion: Elaprase and Avlayah

    ALL of the following

    • Elaprase is not being used to treat MPS II in combination with Avlayah.

    Disease-Modifying Therapy Exclusion: Elfabrio

    ALL of the following

    • Elfabrio is not being received in combination with another disease-modifying therapy for Fabry disease, including Fabrazyme or Galafold.

    Disease-Modifying Therapy Exclusion: Fabrazyme

    ALL of the following

    • Fabrazyme is not being received in combination with another disease-modifying therapy for Fabry disease, including Elfabrio or Galafold.

    CNS Manifestation Exclusion: Lamzede

    ALL of the following

    • Lamzede is not being used to treat central nervous system manifestations of alpha-mannosidosis.

    Concurrent Enzyme Therapy Exclusion: Pompe Disease

    ALL of the following

    • Lumizyme is not being received in combination with Nexviazyme or Pombiliti.
    • Nexviazyme is not being received in combination with Lumizyme or Pombiliti.
    • Pombiliti is not being received in combination with Lumizyme or Nexviazyme.

    CNS Manifestation Exclusion: Xenpozyme

    ALL of the following

    • Xenpozyme is not being used to treat central nervous system manifestations of ASMD.

    Combination Therapy Exclusion: Avlayah and Elaprase

    ALL of the following

    • Avlayah and Elaprase may not be used in combination for treatment of MPS II.

    Combination Therapy Exclusion: Fabrazyme

    ALL of the following

    • Fabrazyme may not be used in combination with another disease-modifying Fabry disease therapy, including Elfabrio or Galafold.

    Applicable Codes and Coding Requirements

    HCPCS codes referenced in state-specific application instructionsHCPCS
    J0221Lumizyme
    J0219Nexviazyme
    J1203Pombiliti
    Aldurazymemixed
    J1931Injection, laronidase, 0.1 mg
    E76.01Hurler's syndrome
    E76.02Hurler-Scheie syndrome
    E76.03Scheie's syndrome
    Avlayahmixed
    J1757Injection, tividenofusp alfa-eknm, 1 mg
    E76.1Mucopolysaccharidosis, type II
    Elaprasemixed
    J1743Injection, idursulfase, 1 mg
    E76.1Mucopolysaccharidosis, type II
    Elfabriomixed
    J2508Injection, pegunigalsidase alfa-iwxj, 1 mg
    E75.21Fabry (-Anderson) disease
    Fabrazymemixed
    J0180Injection, agalsidase beta, 1 mg
    E75.21Fabry (-Anderson) disease
    Kanumamixed
    J2840Injection, sebelipase alfa, 1 mg
    E75.5Other lipid storage disorders
    Lamzedemixed
    J0217Injection, velmanase alfa-tycv, 1 mg
    E77.1Defects in glycoprotein degradation
    Loargysmixed
    J1818Injection, pegzilarginase-nbln, 0.05 mg
    E27.21Argininemia
    Lumizymemixed
    J0221Injection, alglucosidase alfa, (Lumizyme), 10 mg
    E74.02Pompe disease
    Mepseviimixed
    J3397Injection, vestronidase alfa-vjbk, 1 mg
    E76.29Other mucopolysaccharidoses (includes Sly syndrome)
    Naglazymemixed
    J1458Injection, galsulfase, 1 mg
    E76.29Other mucopolysaccharidoses (includes Maroteaux-Lamy syndrome)
    Nexviazymemixed
    J0219Injection, avalglucosidase alfa-ngpt, 4 mg
    E74.02Pompe disease
    Nulibrymixed
    J1809Injection, fosdenopterin, 0.1 mg
    E72.10Disorders of sulfur-bearing amino-acid metabolism, unspecified
    E72.19Other disorders of sulfur-bearing amino-acid metabolism
    Pombilitimixed
    J1203Injection, cipaglucosidase alfa-atga, 5 mg
    E74.02Pompe disease
    Revcovimixed
    J3590Unclassified biologic
    D81.31Severe combined immunodeficiency due to adenosine deaminase deficiency
    Vimizimmixed
    J1322Injection, elosulfase alfa, 1mg
    E76.210Morquio A mucopolysaccharidoses
    Xenpozymemixed
    J0218Injection, olipudase alfa-rpcp, 1 mg
    E75.241Niemann-Pick disease type B; also applicable to ASMD type B & Chronic visceral acid sphingomyelinase deficiency
    E75.244Niemann-Pick disease type A/B; ASMD type A/B & Chronic neurovisceral acid sphingomyelinase deficiency
    VimizimHCPCSCovered
    J1322Injection, elosulfase alfa, 1mg
    VimizimICD-10Covered
    E76.210Morquio A mucopolysaccharidoses
    XenpozymeHCPCSCovered
    J0218Injection, olipudase alfa-rpcp, 1 mg
    XenpozymeICD-10Covered
    E75.241Niemann-Pick disease type B; also applicable to ASMD type B & Chronic visceral acid sphingomyelinase deficiency
    E75.244Niemann-Pick disease type A/B; ASMD type A/B & Chronic neurovisceral acid sphingomyelinase deficiency
    Avlayah Applicable CodesmixedCovered
    J1757Avlayah
    E76.1Mucopolysaccharidosis, type II
    Loargys Applicable CodesmixedCovered
    J1818Loargys
    E27.21Arginase deficiency
    Indiana Medicaid policy-directed productsHCPCS
    J0221Lumizyme
    J0219Nexviazyme
    J1203Pombiliti
    Alpha-galactosidase A activity
    Threshold< 5% of mean
    EnzymeAlpha-galactosidase A
    Testing sitesLeukocytes, dried blood spots, or serum analysis
    Alpha-mannosidase activity
    Threshold< 10% of the lab-specific normal mean
    EnzymeAlpha-mannosidase
    Related diagnosisAlpha-mannosidosis
    Acid alpha-glucosidase activity
    Threshold< 1% of the lab-specific normal mean
    EnzymeAcid alpha-glucosidase (GAA)
    Related conditionInfantile-onset Pompe disease
    Infantile-onset Pompe GAA activity
    Threshold<1% of the laboratory-specific normal mean
    Disease subtypeInfantile-onset Pompe disease
    Alternative confirmationMolecular genetic testing for deletion or mutations in the GAA gene
    Late-onset Pompe GAA activity
    Threshold<40% of the laboratory-specific normal mean
    Disease subtypeLate-onset Pompe disease
    Testing sitesLymphocytes, fibroblasts, or muscle
    Pombiliti minimum patient weight
    Minimum weight≥40 kg
    TherapyPombiliti
    Required combinationOral Opfolda (miglustat)
    MoCD type A symptom timing
    TimingWithin the first 28 days after birth
    ConditionMolybdenum cofactor deficiency type A
    Examples of symptomsSeizures, exaggerated startle response, high-pitched cry, hypotonia, hypertonia, or feeding difficulties
    Authorization period
    Initial authorizationNo more than 12 months
    ReauthorizationNo more than 12 months
    Continuation basisPrior treatment and a positive clinical response, where continuation criteria are provided

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required for Listed Therapies

    Obtain prior authorization before providing Aldurazyme, Avlayah, Elaprase, Elfabrio, Fabrazyme, Kanuma, Lamzede, Loargys, Lumizyme, Mepsevii, Naglazyme, Nexviazyme, Nulibry, Pombiliti, Revcovi, Vimizim, or Xenpozyme. Coverage is contingent on meeting the applicable drug-specific criteria.

    • Applies to the enzyme-deficiency medical therapies listed in the policy.
    • Submit documentation supporting the product-specific diagnosis, laboratory or genetic confirmation, clinical findings, dosing, and treatment history as applicable.
    Prior Authorization

    Authorization Periods Are Limited to 12 Months

    Initial authorization and reauthorization for covered products are limited to periods of no more than 12 months. Continuation requests must document prior treatment and the required positive clinical response when specified.

    • Initial authorization: no more than 12 months.
    • Reauthorization: no more than 12 months.
    • Continuation requests must include product-specific treatment response and any ongoing exclusions or combination requirements.
    Documentation Required

    Vimizim Authorization Criteria

    For Vimizim, document Morquio A syndrome (MPS IVA) and satisfy the initial or continuation criteria before requesting authorization.

    • Confirm GALNS enzyme deficiency or a pathogenic GALNS mutation.
    • Document clinical findings such as kyphoscoliosis, genu valgum, pectus carinatum, gait disturbance, or growth deficiency.
    • For continuation, document prior elosulfase alfa use and positive response, such as improved endurance, functional capacity, or reduced urine keratan sulfate.
    Documentation Required

    Xenpozyme Authorization Criteria

    For Xenpozyme, document ASMD type A/B or type B, clinically significant disease manifestations, and compliance with the CNS exclusion and FDA-labeled dosing requirements.

    • Confirm ASMD by deficient acid sphingomyelinase activity or SMPD1 molecular testing.
    • Document clinical findings such as hepatosplenomegaly, elevated transaminases, mixed dyslipidemia, or abnormal pulmonary function.
    • For continuation, document prior olipudase alfa use and positive response.
    Documentation Required

    Avlayah and Loargys Documentation

    For new-product requests involving Avlayah or Loargys, submit clinical and diagnostic documentation demonstrating the applicable disease and all initial or continuation requirements.

    • Avlayah: document MPS II confirmation, clinical manifestations, no combination use with Elaprase, dosing, and authorization history/response as applicable.
    • Loargys: document hyperargininemia due to arginase 1 deficiency, clinical manifestations, dosing, and authorization history/response as applicable.
    Documentation Required

    Fabrazyme Authorization Criteria

    For Fabrazyme requests, document Fabry disease confirmation, clinical manifestations, prohibited combination therapies, FDA-labeled dosing, and the applicable initial or continuation requirements.

    • Confirm deficient alpha-galactosidase A activity or a galactosidase alpha gene mutation.
    • For continuation, document prior agalsidase beta treatment and positive clinical response.
    Documentation Required

    Aldurazyme Documentation

    For Aldurazyme, submit documentation confirming an MPS I syndrome and alpha-L-iduronidase deficiency or a qualifying alpha-L-iduronidase gene mutation, together with clinical findings and the applicable treatment history.

    • Identify Hurler, Hurler-Scheie, or Scheie MPS I variant.
    • Document fibroblast or leukocyte enzyme deficiency/absence or molecular genetic confirmation.
    • For continuation, document prior laronidase treatment and positive clinical response.
    Documentation Required

    Avlayah Documentation

    For Avlayah, submit documentation confirming MPS II, neurologic or other clinical manifestations, and the required treatment status. Avlayah must not be used with Elaprase for MPS II.

    • Confirm iduronate 2-sulfatase deficiency with normal activity of another sulfatase or confirm an iduronate 2-sulfatase gene deletion/mutation.
    • Document manifestations such as hepatosplenomegaly, skeletal deformities, dysostosis, neurocognitive decline, or cardiovascular disorders.
    • For continuation, document prior tividenofusp alfa treatment and positive response.
    Documentation Required

    Elaprase Documentation

    For Elaprase, submit documentation confirming MPS II, clinical manifestations, and the required treatment status. Elaprase must not be used with Avlayah for MPS II.

    • Confirm iduronate 2-sulfatase deficiency with normal activity of another sulfatase or confirm an iduronate 2-sulfatase gene deletion/mutation.
    • For continuation, document prior idursulfase treatment and positive response.
    Documentation Required

    Elfabrio Documentation

    For Elfabrio, submit documentation confirming Fabry disease, relevant clinical manifestations, and that the patient is not receiving another Fabry disease-modifying therapy.

    • Confirm alpha-galactosidase A activity below 5% of the mean or a galactosidase alpha gene deletion/mutation.
    • For continuation, document prior pegunigalsidase alfa-iwxj treatment and positive response.
    • Document FDA-labeled dosing.
    Documentation Required

    Fabrazyme Documentation

    For Fabrazyme, submit documentation confirming Fabry disease, relevant clinical manifestations, and that the patient is not receiving another Fabry disease-modifying therapy.

    • Confirm alpha-galactosidase A activity below 5% of the mean or a galactosidase alpha gene deletion/mutation.
    • For continuation, document prior agalsidase beta treatment and positive response.
    • Document FDA-labeled dosing.
    Documentation Required

    Kanuma Documentation

    For Kanuma, document lysosomal acid lipase deficiency and the associated clinical disease, along with dosing and treatment response requirements.

    • Confirm deficient lysosomal acid lipase activity by dried blood spot or a qualifying LIPA mutation.
    • Document clinical findings such as abdominal distention, hepatosplenomegaly, liver fibrosis, or ascites.
    • For continuation, document prior sebelipase alfa treatment and positive response.
    Documentation Required

    Lamzede Documentation

    For Lamzede, document alpha-mannosidosis, associated clinical findings, and the exclusion of CNS-directed use.

    • Confirm alpha-mannosidase deficiency below 10% of the laboratory-specific normal mean or a MAN2B1 mutation.
    • Document findings such as hepatosplenomegaly, skeletal abnormalities, ataxia, intellectual disability, or hearing loss.
    • For continuation, document prior velmanase alfa-tycv treatment and positive response.
    Documentation Required

    Loargys Documentation

    For Loargys, submit diagnostic, clinical, dosing, and treatment-response documentation for arginase 1 deficiency.

    • Confirm hyperargininemia by deficient arginase 1 activity or ARG1 genetic variants.
    • Document loss of motor skills, intellectual disability, developmental delay, or other clinical manifestations.
    • For continuation, document prior pegzilarginase treatment and positive response.
    Documentation Required

    Lumizyme Documentation

    For Lumizyme, submit documentation confirming Pompe disease, the applicable age-onset category, clinical manifestations, and the required treatment status and response.

    • Infantile-onset Pompe: document GAA activity below 1% of the laboratory-specific normal mean in skin fibroblasts or a qualifying GAA mutation.
    • Late-onset Pompe: document GAA activity below 40% of the laboratory-specific normal mean in lymphocytes, fibroblasts, or muscle, or a qualifying GAA mutation.
    • Document clinical findings such as cardiac hypertrophy, respiratory distress, or skeletal muscle weakness.
    • For continuation, document prior alglucosidase alfa treatment and positive clinical response.
    Documentation Required

    Diagnostic Laboratory or Genetic Confirmation

    Use laboratory testing or molecular genetic testing to establish the applicable enzyme-deficiency diagnosis before requesting authorization.

    • Accepted evidence varies by product and may include deficient enzyme activity, dried blood spot testing, fibroblast/leukocyte testing, or molecular confirmation of disease-specific gene mutations.
    • Include the actual test results or genetic report in the authorization submission.
    Documentation Required

    Clinical Findings and Treatment Response

    Submit records demonstrating the disease manifestations and, for continuation, a positive response to the requested therapy.

    • Initial requests generally require clinical signs and symptoms supporting active disease.
    • Continuation requests require product-specific evidence of improvement or favorable clinical/laboratory response.
    • Examples include improved endurance or function, improved respiratory/cardiac or pulmonary status, reduced organ volume, or improved disease biomarkers.
    Documentation Required

    Pombiliti-Specific Documentation

    For Pombiliti, document all product-specific requirements, including the late-onset Pompe diagnosis, lack of improvement on current ERT, weight, Opfolda use, and discontinuation of the current ERT.

    • Provider attestation: the patient is not improving on current Lumizyme or Nexviazyme and that therapy will be stopped.
    • Patient weight must be at least 40 kg.
    • Pombiliti must be prescribed with oral Opfolda (miglustat).
    • For continuation, document positive response to Pombiliti plus Opfolda.
    Documentation Required

    Revcovi Transplant-Related Documentation

    For Revcovi, document ADA-SCID, laboratory or genetic confirmation of ADA deficiency, and the patient’s transplant-related status.

    • Acceptable confirmation may include deficient ADA, elevated erythrocyte dATP, decreased erythrocyte ATP, biallelic ADA1 mutations, or positive TREC screening.
    • Document that the patient is not a suitable HCT candidate, has failed HCT, or is awaiting HCT.
    • For continuation, document prior elapegademase-lvlr treatment and positive response.
    Documentation Required

    ASMD Diagnostic Confirmation

    For Xenpozyme, provide diagnostic confirmation of ASMD before authorization.

    • Confirm absent or deficient acid sphingomyelinase activity or mutations in SMPD1.
    • The covered disease is ASMD type A/B or type B.
    • Document clinical manifestations and do not request treatment for CNS manifestations.
    Documentation Required

    Morquio A Treatment Documentation

    For Vimizim, document Morquio A diagnostic confirmation, clinical manifestations, FDA-labeled dosing, and response to prior therapy when requesting continuation.

    • Confirm deficient GALNS activity in fibroblasts or leukocytes or a GALNS mutation.
    • For continuation, document prior elosulfase alfa treatment and positive response, including improved endurance/function or reduced urine keratan sulfate.

    Unsupported block type: documentation

    Denial Risk

    Do Not Combine Avlayah With Elaprase

    Avlayah is not covered when used to treat MPS II in combination with Elaprase. Requests that show concurrent use of both products may be denied.

    • Apply the exclusion during both initial authorization and continuation.
    • Document that the requested regimen does not include Elaprase for MPS II.
    Denial Risk

    Do Not Combine Elaprase With Avlayah

    Elaprase is not covered when used to treat MPS II in combination with Avlayah. Requests that show concurrent use of both products may be denied.

    • Apply the exclusion during both initial authorization and continuation.
    • Document that the requested regimen does not include Avlayah for MPS II.
    Denial Risk

    Elfabrio Combination Therapy Exclusion

    Elfabrio is not covered when used with another Fabry disease-modifying therapy, including Fabrazyme or Galafold. Concurrent combination therapy may result in denial.

    • The exclusion applies to initial and continuation requests.
    • Document the patient’s complete Fabry treatment regimen.
    Denial Risk

    Fabrazyme Combination Therapy Exclusion

    Fabrazyme is not covered when used with another Fabry disease-modifying therapy, including Elfabrio or Galafold. Concurrent combination therapy may result in denial.

    • The exclusion applies to initial and continuation requests.
    • Document the patient’s complete Fabry treatment regimen.
    Denial Risk

    Lamzede CNS Use Exclusion

    Lamzede is not covered for treatment of central nervous system manifestations of alpha-mannosidosis.

    • Request coverage only for the non-CNS disease manifestations addressed by the policy.
    Denial Risk

    Concurrent Pompe Disease Enzyme Therapy

    Do not use Lumizyme, Nexviazyme, or Pombiliti concurrently with another disease-modifying enzyme therapy for Pompe disease when the applicable product criteria prohibit the combination.

    • Lumizyme may not be combined with Nexviazyme or Pombiliti.
    • Nexviazyme may not be combined with Lumizyme or Pombiliti.
    • Pombiliti may not be combined with Lumizyme or Nexviazyme.
    Denial Risk

    Failure to Improve on Current ERT

    For Pombiliti, the provider must attest that the patient is not improving on current ERT and that the current therapy will be stopped.

    • Current ERT includes Lumizyme or Nexviazyme.
    • Failure to document lack of improvement and discontinuation of current ERT may result in denial.
    Denial Risk

    Pombiliti Weight and Combination Requirements

    Pombiliti requires a patient weight of at least 40 kg and concurrent oral Opfolda (miglustat); current Pompe ERT must be stopped.

    • Weight: ≥ 40 kg.
    • Combination: Pombiliti plus Opfolda.
    • Do not use with Lumizyme or Nexviazyme.
    Denial Risk

    Xenpozyme CNS Use Exclusion

    Xenpozyme is not covered for treatment of central nervous system manifestations of ASMD.

    • Request coverage only for the systemic ASMD manifestations addressed by the policy.
    Billing Rule

    FDA-Label Dosing Required

    Administer each requested product according to its FDA-approved labeling and document the prescribed dose and schedule in the authorization submission.

    • FDA-labeled dosing is an initial and/or continuation requirement across the listed products.
    • A dosing regimen outside FDA-approved labeling may result in denial.
    Denial Risk

    Xenpozyme CNS Manifestation Exclusion

    Xenpozyme must not be used for CNS manifestations of ASMD; the policy addresses systemic disease manifestations such as organomegaly, liver abnormalities, dyslipidemia, and pulmonary impairment.

    • Document the specific systemic manifestations being treated.
    • CNS-directed use is excluded.
    Denial Risk

    Labeling and Authorization Limits

    Coverage is limited to the diseases, indications, dosing, treatment combinations, and authorization periods described in the applicable drug-specific criteria.

    • Requests must satisfy all required initial or continuation criteria.
    • Excluded CNS use, prohibited combinations, missing diagnostic evidence, absent clinical support, or non-FDA-labeled dosing may be denied.
    Denial Risk

    Concurrent Elaprase Use

    Avlayah must not be used concurrently with Elaprase for treatment of MPS II.

    • Document that the requested Avlayah regimen excludes concurrent Elaprase.
    Denial Risk

    Concurrent Fabry Disease Therapy

    Fabrazyme must not be used concurrently with another Fabry disease-modifying therapy, including Elfabrio or Galafold.

    • Document the complete Fabry treatment regimen and confirm that prohibited concurrent therapy is not being used.
    Denial Risk

    Failure to Meet Drug-Specific Criteria

    Requests that do not meet the applicable drug-specific diagnostic, clinical, dosing, combination, treatment-response, or authorization-period requirements are not eligible for coverage.

    • Submit complete laboratory/genetic confirmation and clinical documentation.
    • Correct deficiencies before resubmission when possible.

    Policy Background

    This policy addresses therapies for rare inherited disorders caused by deficient or absent enzymes, including mucopolysaccharidoses, Fabry disease, lysosomal acid lipase deficiency, alpha-mannosidosis, hyperargininemia, and Pompe disease. Coverage generally requires biochemical or molecular confirmation of the enzyme deficiency, compatible clinical manifestations, FDA-labeled dosing, and evidence of a positive clinical response for continued treatment.

    Disease and Clinical Definitions

    Hurler variant
    SeveritySevere mucopolysaccharidosis I
    Also calledMPS IH
    Associated therapyAldurazyme is used for MPS I syndromes
    Hurler-Scheie variant
    Disease courseAttenuated mucopolysaccharidosis I
    Also calledMPS IHS
    Disease groupMucopolysaccharidosis I
    Scheie variant
    Disease courseAttenuated mucopolysaccharidosis I
    Also calledMPS IS
    Disease groupMucopolysaccharidosis I
    LAL-D definition
    Full nameLysosomal acid lipase deficiency
    Included formWolman disease (WD)
    Included formCholesteryl ester disease (CESD)
    Hyperarginemia definition
    Underlying deficiencyArginase 1 deficiency
    Clinical conditionHyperargininemia
    ConfirmationAbsent or deficient arginase 1 enzyme activity or genetic variants in the ARG1 gene
    Pompe disease definition
    DiseasePompe disease
    SubtypesInfantile-onset or late-onset
    Late-onset supportAcid alpha-glucosidase activity below 40% of the laboratory-specific normal mean or qualifying GAA gene testing
    MPS VII definition
    Full nameMucopolysaccharidosis VII
    AbbreviationMPS VII
    Also calledSly syndrome
    MPS VI definition
    Full nameMucopolysaccharidosis VI
    AbbreviationMPS VI
    Also calledMaroteaux-Lamy syndrome
    MPS IVA definition
    Full nameMucopolysaccharidosis type IVA
    AbbreviationMPS IVA
    Also calledMorquio A syndrome
    ASMD definition
    Full nameAcid sphingomyelinase deficiency
    Included typesType A/B or type B disease
    Diagnostic basisAbsent or deficient acid sphingomyelinase activity or SMPD1 molecular testing
    Acid sphingomyelinase deficiency definition
    ConditionAcid sphingomyelinase deficiency (ASMD)
    ConfirmationAbsent or deficient acid sphingomyelinase enzyme activity or molecular genetic testing for SMPD1 mutations
    Types addressedASMD type A/B or type B
    MPS II definition
    Full nameMucopolysaccharidosis type II
    AbbreviationMPS II
    Also calledHunter syndrome
    MPS IVA definition
    Full nameMucopolysaccharidosis type IVA
    AbbreviationMPS IVA
    Also calledMorquio A syndrome
    ASMD treatment scope
    ConditionAcid sphingomyelinase deficiency (ASMD)
    Treatment scopeNon-central nervous system manifestations
    Applicable populationAdults and pediatric patients
    Arginase 1 deficiency definition
    ConditionArginase 1 deficiency
    Clinical resultHyperargininemia
    ConfirmationAbsent or deficient arginase 1 activity or pathogenic ARG1 gene variants

    Initial Therapy Decision Criteria

    Aldurazyme initial therapy

    All of the following are required.

    MPS I diagnosis with qualifying syndrome; enzyme or molecular confirmation; clinical signs and symptoms; FDA-approved dosing; and initial authorization no more than 12 months.

    Avlayah initial therapy

    All of the following are required.

    Confirmed MPS II; clinical signs and symptoms; no concurrent Elaprase; FDA-approved dosing; and initial authorization no more than 12 months.

    Elaprase initial therapy

    All of the following are required.

    Confirmed MPS II; clinical signs and symptoms; no concurrent Avlayah; FDA-approved dosing; and initial authorization no more than 12 months.

    Elfabrio initial therapy

    All of the following are required.

    Confirmed Fabry disease; clinical signs and symptoms; no concurrent disease-modifying Fabry therapy; FDA-approved dosing; and initial authorization no more than 12 months.Alpha-galactosidase A activity < 5% of mean

    Fabrazyme initial therapy

    All of the following are required.

    Confirmed Fabry disease; clinical signs and symptoms; no concurrent disease-modifying Fabry therapy; FDA-approved dosing; and initial authorization no more than 12 months.Alpha-galactosidase A activity < 5% of mean

    Kanuma initial therapy

    All of the following are required.

    Confirmed LAL-D, Wolman disease, or cholesteryl ester disease; clinical signs and symptoms; FDA-approved dosing; and initial authorization no more than 12 months.

    Lamzede initial therapy

    All of the following are required.

    Confirmed alpha-mannosidosis; clinical signs and symptoms; no CNS treatment target; FDA-approved dosing; and initial authorization no more than 12 months.Alpha-mannosidase activity < 10% of laboratory-specific normal mean

    Loargys initial therapy

    All of the following are required.

    Confirmed hyperargininemia due to arginase 1 deficiency; clinical signs and symptoms; FDA-approved dosing; and initial authorization no more than 12 months.

    Lumizyme initial therapy pathway

    Meet all criteria in either the infantile-onset or late-onset pathway.

    ANY of the following

    • Infantile-onset Pompe: GAA activity below 1% of the laboratory-specific normal mean or qualifying GAA genetic testing; clinical signs and symptoms; no prohibited combination therapy; FDA-approved dosing; authorization no more than 12 months.
    • Late-onset Pompe: GAA activity below 40% of the laboratory-specific normal mean or qualifying GAA genetic testing; clinical signs and symptoms; no prohibited combination therapy; FDA-approved dosing; authorization no more than 12 months.

    Lumizyme infantile-onset or late-onset pathways

    Initial therapy is covered through one of the following pathways.

    ANY of the following

    • Infantile-onset pathway: Confirmed infantile-onset Pompe disease, GAA activity below 1% or qualifying GAA testing, clinical signs and symptoms, no prohibited combination therapy, FDA-approved dosing, and authorization no more than 12 months.
    • Late-onset pathway: Confirmed late-onset Pompe disease, GAA activity below 40% or qualifying GAA testing, clinical signs and symptoms, no prohibited combination therapy, FDA-approved dosing, and authorization no more than 12 months.

    Other therapies initial therapy criteria

    Each requested product must meet all applicable product-specific criteria.

    The requested therapy has the required diagnostic confirmation, clinical signs and symptoms, FDA-approved dosing, and initial authorization no more than 12 months; product-specific restrictions also apply, including no prohibited Pompe combination therapy, Pombiliti weight of at least 40 kg with Opfolda, Nulibry symptoms within 28 days after birth, Revcovi HCT eligibility, and no CNS use for Xenpozyme.

    Xenpozyme initial therapy

    All of the following are required.

    ASMD type A/B or B confirmed by absent or deficient acid sphingomyelinase activity or SMPD1 molecular testing; clinical signs and symptoms; no CNS treatment target; FDA-approved dosing; and initial authorization no more than 12 months.

    Drug-specific initial therapy criteria

    Initial therapy requires all criteria specified for the requested drug.

    Avlayah: Confirmed MPS II, clinical signs and symptoms, no concurrent Elaprase, FDA-approved dosing, and initial authorization no more than 12 months.
    Loargys: Confirmed hyperargininemia due to arginase 1 deficiency, clinical signs and symptoms, FDA-approved dosing, and initial authorization no more than 12 months.
    Fabrazyme: Confirmed Fabry disease, clinical signs and symptoms, no concurrent disease-modifying Fabry therapy, FDA-approved dosing, and initial authorization no more than 12 months.Alpha-galactosidase A activity < 5% of mean

    Continuation and Reauthorization Criteria

    Aldurazyme continuation

    All of the following are required.

    Previous laronidase treatment; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months.

    Avlayah continuation

    All of the following are required.

    Previous tividenofusp alfa treatment; positive clinical response; no concurrent Elaprase; FDA-approved dosing; and reauthorization no more than 12 months.

    Elaprase continuation

    All of the following are required.

    Previous idursulfase treatment; positive clinical response; no concurrent Avlayah; FDA-approved dosing; and reauthorization no more than 12 months.

    Elfabrio continuation

    All of the following are required.

    Previous pegunigalsidase alfa-iwxj treatment; positive clinical response; no concurrent disease-modifying Fabry therapy; FDA-approved dosing; and reauthorization no more than 12 months.

    Fabrazyme continuation

    All of the following are required.

    Previous agalsidase beta treatment; positive clinical response; no concurrent disease-modifying Fabry therapy; FDA-approved dosing; and reauthorization no more than 12 months.

    Kanuma continuation

    All of the following are required.

    Previous sebelipase alfa treatment; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months.

    Lamzede continuation

    All of the following are required.

    Previous velmanase alfa-tycv treatment; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months.

    Loargys continuation

    All of the following are required.

    Previous pegzilarginase treatment; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months.

    Pegzilarginase continuation

    All of the following are required.

    Previous pegzilarginase treatment; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months.

    Lumizyme continuation

    All of the following are required.

    Previous alglucosidase alfa treatment; positive clinical response; no concurrent disease-modifying Pompe enzyme therapy; FDA-approved dosing; and reauthorization no more than 12 months.

    Other therapies continuation criteria

    Continuation requires all applicable product-specific criteria.

    Previous treatment with the requested therapy; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months. Product-specific requirements also apply, including continued Opfolda with Pombiliti, no concurrent Pompe enzyme therapy where specified, and the applicable response measure for the disease.

    Vimizim continuation

    All of the following are required.

    Previous elosulfase alfa treatment; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months.

    Xenpozyme continuation

    All of the following are required.

    Previous olipudase alfa-rpcp treatment; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months.

    Avlayah and Loargys continuation

    Continuation requires all criteria for the applicable drug.

    Avlayah: Previous tividenofusp alfa treatment; positive clinical response; no concurrent Elaprase; FDA-approved dosing; and reauthorization no more than 12 months.
    Loargys: Previous pegzilarginase treatment; positive clinical response; FDA-approved dosing; and reauthorization no more than 12 months.

    Fabrazyme continuation

    All of the following are required.

    Previous agalsidase beta treatment; positive clinical response; no concurrent disease-modifying Fabry therapy; FDA-approved dosing; and reauthorization no more than 12 months.